Edition:
India

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

8.93USD
19 Jan 2018
Change (% chg)

$0.04 (+0.45%)
Prev Close
$8.89
Open
$8.84
Day's High
$9.00
Day's Low
$8.74
Volume
30,329
Avg. Vol
24,805
52-wk High
$10.55
52-wk Low
$5.85

Chart for

About

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product... (more)

Overall

Beta: -0.54
Market Cap(Mil.): $171.73
Shares Outstanding(Mil.): 19.06
Dividend: --
Yield (%): --

Financials

BRIEF-Recro Pharma - ‍Ryan Lake Promoted To CFO

* RECRO PHARMA INC - ‍RYAN D. LAKE HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER​ Source text for Eikon: Further company coverage:

03 Jan 2018

BRIEF-Recro Pharma Says Entered Into A Sales Agreement With Cowen And Co‍​

* RECRO PHARMA INC - ENTERED INTO A SALES AGREEMENT WITH COWEN AND COMPANY‍​

30 Dec 2017

BRIEF-Recro Pharma secures $100 million credit facility

* Recro Pharma Inc - ‍has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP​

20 Nov 2017

BRIEF-Recro Pharma reports Q3 revenue $17.1 million

* Recro Pharma Inc - ‍Raising its guidance for 2017 revenue from a range of $60-$63 million to $65 million​

09 Nov 2017

BRIEF-RECRO PHARMA ANNOUNCES PDUFA DATE OF MAY 26, 2018 FOR IV MELOXICAM 30MG

* RECRO PHARMA - U.S. FDA HAS SET A PDUFA DATE OF MAY 26, 2018 FOR ITS DECISION ON NEW DRUG APPLICATION (NDA) FOR INTRAVENOUS (IV) MELOXICAM 30MG Source text for Eikon: Further company coverage:

05 Oct 2017

BRIEF-Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg

* Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

28 Sep 2017

BRIEF-Recro Pharma quarterly ‍loss per share $0.48

* Qtrly ‍loss per share $0.48; Co is raising its guidance for 2017 revenue from a range of $55-$60 million to $60-$63 million​ Source text for Eikon: Further company coverage:

10 Aug 2017

BRIEF-Recro Pharma submits new drug application for IV Meloxicam 30mg

* Recro Pharma submits new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage:

31 Jul 2017

Earnings vs. Estimates